BibTex format
@article{Barsosio:2026:10.1016/S2214-109X(25)00541-8,
author = {Barsosio, HC and Tangara, B and Marlais, T and Kabor茅, JMT and Tiono, AB and Otieno, K and Wanjiku, M and Achieng, M and Onyango, ED and Ondieki, ED and Aura, H and Odawo, T and Allen, DJ and Hannan, L and Tetteh, KKA and Soulama, I and Ouedraogo, A and Serme, SS and Soulama, BI and Barry, A and Badoum, ES and Matthewman, J and Brazal-Monz贸, H and Canizales, J and Drabko, A and Wu, W and Kariuki, S and Lesosky, M and Sirima, SB and Drakeley, C and Ter, Kuile FO},
doi = {10.1016/S2214-109X(25)00541-8},
journal = {Lancet Glob Health},
pages = {e793--e805},
title = {Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort study.},
url = {http://dx.doi.org/10.1016/S2214-109X(25)00541-8},
volume = {14},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: The relationship between malaria and COVID-19 varies across different clinical scenarios; historical malaria exposure might protect against severe COVID-19, whereas co-infection in hospitalised patients with severe disease might increase mortality. Interactions between non-severe malaria and COVID-19 remain poorly understood. We conducted a cohort study among COVID-19 patients of all ages in western Kenya and Burkina Faso to assess the effects of acute, uncomplicated Plasmodium falciparum malaria co-infection on COVID-19 outcomes in ambulatory patients. METHODS: Participants with laboratory-confirmed SARS-CoV-2 infection (positive rapid antigen test or reverse transcription quantitative real-time PCR [RT-qPCR]) were tested for malaria by rapid antigen tests with confirmatory microscopy. Patients with COVID-19 and malaria co-infection received artemether-lumefantrine or pyronaridine-artesunate. COVID-19 symptom course was assessed daily using FLU-PRO Plus (a validated patient-reported outcome instrument) until day 14. Viral load was measured by RT-qPCR on days 0, 3, 7, 14, and 28. The primary endpoint was time to symptom resolution on the FLU-PRO Plus. Analyses were adjusted for country, age, disease severity, and viral load. FINDINGS: Between Jan 8, 2021 and Jan 24, 2022, we screened 5161 participants and recruited 756 with COVID-19. 742 participants with valid malaria tests were enrolled, of which 151 (20%) had malaria co-infection and the remaining 591 (80%) did not have malaria. Patients with malaria were younger (49 [32%] aged <15 years) than those without malaria (35 [6%]; p<0·0001). Time to symptom resolution was similar between those with malaria (median 9 days [IQR 5-13]) and those without (10 days [IQR 6-13]; adjusted hazard ratio [aHR] 1·14 [95% CI 0·91-1·42]; p=0·26). Three (2%) patients with malaria and nine (2%) without malaria were hospitalised; two (1%) with malaria and three (1%) without malaria di
AU - Barsosio,HC
AU - Tangara,B
AU - Marlais,T
AU - Kabor茅,JMT
AU - Tiono,AB
AU - Otieno,K
AU - Wanjiku,M
AU - Achieng,M
AU - Onyango,ED
AU - Ondieki,ED
AU - Aura,H
AU - Odawo,T
AU - Allen,DJ
AU - Hannan,L
AU - Tetteh,KKA
AU - Soulama,I
AU - Ouedraogo,A
AU - Serme,SS
AU - Soulama,BI
AU - Barry,A
AU - Badoum,ES
AU - Matthewman,J
AU - Brazal-Monz贸,H
AU - Canizales,J
AU - Drabko,A
AU - Wu,W
AU - Kariuki,S
AU - Lesosky,M
AU - Sirima,SB
AU - Drakeley,C
AU - Ter,Kuile FO
DO - 10.1016/S2214-109X(25)00541-8
EP - 805
PY - 2026///
SP - 793
TI - Uncomplicated malaria as a risk factor for COVID-19 duration and severity in western Kenya and Burkina Faso (MALCOV): a prospective cohort study.
T2 - Lancet Glob Health
UR - http://dx.doi.org/10.1016/S2214-109X(25)00541-8
UR - https://www.ncbi.nlm.nih.gov/pubmed/41999717
VL - 14
ER -
